The Seattle eMERGE project aims to bring personal genomics to practice settings by taking advantage of the extensive electronic medical record (EMR) and biorepository of Group Health Cooperative (GH), including a 33-year pharmacy database and longitudinal data on an aging population. Algorithms developed in eMERGE I will be used to combine genome-wide association studies with phenotypes mined from EMRs to discover new polymorphism-phenotype relationships. Target phenotypes are infectious disease susceptibility, specifically to Clostridium difficile diarrhea, shingles from varicella zoster virus, and fungal nail infection, responses to antihypertensive drugs, serotonin-specific reuptake inhibitors, and statins, including adverse events. A new algorithm will follow longitudinal glycemia and hematocrit trajectories, and a novel automated method will detect karyotype abnormalities for assessing correlation to myelodysplasia and leukemia. Data will also support phenotypes investigated at other eMERGE sites. To create a model for introducing genomics into clinical practice, successful needs assessment methods from eMERGE I will engage stakeholders in guiding development of prototype EMR user interfaces in a clinical decision support format. The test case will be human leukocyte antigen-typing for an adverse drug reaction and the setting will be the patient-centered medical home care model developed at GH. This proposal provides the eMERGE network and its collaborators with the Seattle team's unique expertise in using natural language processing (NLP) to extract information from EMRs, and assisting in adoption of NLP methods. To disseminate eMERGE results and foster collaborations, it takes advantage of leadership positions of the investigators, including partners within eMERGE, other consortia and the HMO Research network, especially the potential for developments supported by the NIH Director's Common Fund in biobanking and megaepidemiology. Completion of the aims will reveal new, medically useful markers, improve the linking of high-throughput genomic methods to EMR data, and develop policies and practices for bringing individualized evidence-based medicine to communities.

Public Health Relevance

To advance personalized medicine-treatment and preventive care based on individual traits;this project matches small differences in DNA to infectious disease susceptibility and response to statins, serotonin- specific reuptake inhibitors (SSRIs) and blood pressure medications. Methods to use these results in clinical care will be guided by focus groups of patients and caregivers in the patient-centered Group Health system.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HG006375-03
Application #
8517791
Study Section
Special Emphasis Panel (ZHG1-HGR-N (M1))
Program Officer
Li, Rongling
Project Start
2011-08-15
Project End
2015-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
3
Fiscal Year
2013
Total Cost
$935,039
Indirect Cost
$147,968
Name
Group Health Cooperative
Department
Type
DUNS #
078198520
City
Seattle
State
WA
Country
United States
Zip Code
98101
Sun, Xiangqing; Lu, Qing; Mukherjee, Shubhabrata et al. (2014) Analysis pipeline for the epistasis search - statistical versus biological filtering. Front Genet 5:106
Rasmussen, Luke V; Thompson, Will K; Pacheco, Jennifer A et al. (2014) Design patterns for the development of electronic health record-driven phenotype extraction algorithms. J Biomed Inform 51:280-6
Jarvik, Gail P; Amendola, Laura M; Berg, Jonathan S et al. (2014) Return of genomic results to research participants: the floor, the ceiling, and the choices in between. Am J Hum Genet 94:818-26
Schrodi, Steven J; Mukherjee, Shubhabrata; Shan, Ying et al. (2014) Genetic-based prediction of disease traits: prediction is very difficult, especially about the future. Front Genet 5:162
Escott-Price, Valentina; Bellenguez, CĂ©line; Wang, Li-San et al. (2014) Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. PLoS One 9:e94661
Shirts, Brian H; Jacobson, Angela; Jarvik, Gail P et al. (2014) Large numbers of individuals are required to classify and define risk for rare variants in known cancer risk genes. Genet Med 16:529-34
Brothers, Kyle B; Lynch, John A; Aufox, Sharon A et al. (2014) Practical guidance on informed consent for pediatric participants in a biorepository. Mayo Clin Proc 89:1471-80
Nelson, Peter T; Estus, Steven; Abner, Erin L et al. (2014) ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol 127:825-43
Sherva, Richard; Tripodis, Yorghos; Bennett, David A et al. (2014) Genome-wide association study of the rate of cognitive decline in Alzheimer's disease. Alzheimers Dement 10:45-52
Ramos, Erin M; Din-Lovinescu, Corina; Berg, Jonathan S et al. (2014) Characterizing genetic variants for clinical action. Am J Med Genet C Semin Med Genet 166C:93-104

Showing the most recent 10 out of 19 publications